Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA.

1. Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events

2. Secondary Factors affecting safety and to confirm the efficacy such as DAS28.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Patients in active polyarticular JIA (restricted to the case of lack of effect by other treatment) during enrollment period (2.5years).

• Patients receiving Enbrel for JIA as diagnosed by a qualified physician.

• Age 5 - 16 years

Exclusion Criteria:

• Patients not administered ENBREL